{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:47Z","timestamp":1792788107201,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"paradigm biopharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Research about pediatric patients\u2019 perspective on mucopolysaccharidosis type VI (MPS VI) and its impact on daily life is limited. We aimed to identify the disease concepts of interest that most impact function and day-to-day life of pediatric patients with MPS VI, and to consider clinical outcome assessments (COAs) that may potentially measure meaningful improvements in these concepts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Potential focus group participants were identified by the National MPS Society (USA) and invited to participate if they self-reported a clinician-provided diagnosis of MPS VI and were 4 to 18\u00a0years, receiving enzyme replacement therapy (ERT), and available to attend a 1-day focus group with their caregiver in Dallas, TX, USA. The focus group consisted of a series of polling and open-ended concept elicitation questions and a cognitive debriefing session. The discussion was audio recorded, transcribed verbatim, and analyzed to identify disease concepts of interest and functional impacts most relevant to participants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, caregivers (n\u2009=\u20099) and patients with MPS VI (n\u2009=\u20099) endorsed that although their children\/they receive ERT, residual symptoms exist and impact health-related quality of life. The key disease concepts of interest identified were impaired mobility, upper extremity and fine motor deficits, pain, and fatigue. Pain was unanimously reported by all patients across many areas of the body and impacted daily activity. Key disease concepts were mapped to a selection of pediatric COAs including generic measures such as PROMIS\u00ae, PODCI, CHAQ, and PedsQL\u2122. Caregivers endorsed the relevance of PODCI and PROMIS Upper Extremity, Mobility, and Pain items and all patients completed the NIH Toolbox Pegboard Dexterity Test. Additional COAs that aligned with the disease concepts included range of motion, the 2- and 6-min walk tests, timed stair climbs, Bruininks-Oseretsky Test of Motor Proficiency, 2nd edition, grip strength, pain visual analog scale, and the Faces Pain Scale-Revised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>An MPS VI focus group of pediatric patients and their caregivers identified impaired mobility, upper extremity and fine motor deficits, pain, and fatigue as key disease concepts of interest. These disease concepts were mapped to existing pediatric COAs, which were provided to the group for endorsement of their relevance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-02113-8","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T07:03:30Z","timestamp":1638428610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): defining and measuring functional impacts in pediatric patients"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0561-5955","authenticated-orcid":false,"given":"Beth","family":"Leiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Duiker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Harmatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"issue":"3","key":"2113_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2741\/4490","volume":"22","author":"P Harmatz","year":"2017","unstructured":"Harmatz P, Shediac R. Mucopolysaccharidosis VI pathophysiology diagnosis and treatment. Front Biosci. 2017;22(3):385\u2013406.","journal-title":"Front Biosci"},{"issue":"12","key":"2113_CR2","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/humu.23613","volume":"39","author":"R Tomanin","year":"2018","unstructured":"Tomanin R, Karageorgos L, Zanetti A, Al-Sayed M, Bailey M, Miller N, et al. Mucopolysaccharidosis type VI (MPS VI) and molecular analysis: review and classification of published variants in the ARSB gene. Hum Mutat. 2018;39(12):1788\u2013802.","journal-title":"Hum Mutat"},{"issue":"1","key":"2113_CR3","first-page":"47","volume":"3","author":"KK White","year":"2010","unstructured":"White KK, Harmatz P. Orthopedic management of mucopolysaccharide disease. JPediatric Rehabil Med. 2010;3(1):47\u201356.","journal-title":"JPediatric Rehabil Med"},{"issue":"1","key":"2113_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13023-016-0503-2","volume":"11","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Berger KI, Lampe C, Kircher SG, Orchard PJ, Southall R, et al. Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issues. Orphanet J Rare Dis. 2016;11(1):119.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2113_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13023-019-1080-y","volume":"14","author":"MU Akyol","year":"2019","unstructured":"Akyol MU, Alden TD, Amartino H, Ashworth J, Belani K, Berger KI, et al. Recommendations for the management of MPS VI: systematic evidence and consensus-based guidance. Orphanet J Rare Dis. 2019;14(1):118.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"2113_CR6","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","volume":"144","author":"P Harmatz","year":"2004","unstructured":"Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144(5):574\u201380.","journal-title":"J Pediatr"},{"issue":"1","key":"2113_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ymgme.2013.02.013","volume":"109","author":"MMMG Brands","year":"2013","unstructured":"Brands MMMG, Oussoren E, Ruijter GJG, Vollebregt AAM, van den Hout HMP, Joosten KFM, et al. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol Genet Metab. 2013;109(1):70\u20136.","journal-title":"Mol Genet Metab"},{"key":"2113_CR8","doi-asserted-by":"crossref","unstructured":"Brands MMG, G\u00fcng\u00f6r D, van den Hout JMP, Karstens FPJ, Oussoren E, Plug I, et al. Pain: a prevalent feature in patients with mucopolysaccharidosis. Results of a cross-sectional national survey. J Inherit Metab Dis. 2015;38(2):323\u201331.","DOI":"10.1007\/s10545-014-9737-0"},{"issue":"8","key":"2113_CR9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","volume":"164","author":"R Giugliani","year":"2014","unstructured":"Giugliani R, Lampe C, Guffon N, Ketteridge D, Leao-Teles E, Wraith J, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)\u201410-year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A. 2014;164(8):1953\u201364.","journal-title":"Am J Med Genet A"},{"key":"2113_CR10","unstructured":"MAPI Research Trust. PODCI-Self Report - Pediatric Outcomes Data Collection Instrument-Self Report [Internet]. 2021 [cited 2021 Jun 3]. Available from: https:\/\/eprovide.mapi-trust.org\/instruments\/pediatric-outcomes-data-collection-instrument-self-report"},{"key":"2113_CR11","unstructured":"HealthMeasures. PROMIS\u00ae (Patient-Reported Outcomes Measurement Information System) [Internet]. 2021 [cited 2021 Jun 3]. Available from: https:\/\/www.healthmeasures.net\/index.php?option=com_content&view=category&layout=blog&id=147&Itemid=806"},{"issue":"6","key":"2113_CR12","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1097\/00019052-199612000-00011","volume":"9","author":"LB Krupp","year":"1996","unstructured":"Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. Curr Opin Neurol. 1996;9(6):456\u201360.","journal-title":"Curr Opin Neurol"},{"issue":"1","key":"2113_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12969-019-0375-9","volume":"17","author":"M Connelly","year":"2019","unstructured":"Connelly M, Weiss JE, Abramson L, Anderson E, Andrew M, Battle N, et al. Pain, functional disability, and their Association in Juvenile Fibromyalgia Compared to other pediatric rheumatic diseases. Pediatr Rheumatol. 2019;17(1):72.","journal-title":"Pediatr Rheumatol"},{"issue":"10","key":"2113_CR14","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.3390\/ijms19103063","volume":"19","author":"S Congedi","year":"2018","unstructured":"Congedi S, Orzalesi M, Di Pede C, Benini F. Pain in Mucopolysaccharidoses: analysis of the Problem and Possible Treatments. IJMS. 2018;19(10):3063.","journal-title":"IJMS"},{"issue":"10","key":"2113_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.ejpain.2009.08.006","volume":"13","author":"CL von Baeyer","year":"2009","unstructured":"von Baeyer CL. Numerical rating scale for self-report of pain intensity in children and adolescents: Recent progress and further questions. Eur J Pain. 2009;13(10):1005\u20137.","journal-title":"Eur J Pain"},{"issue":"1","key":"2113_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/j.pain.0000000000001377","volume":"160","author":"K Birnie","year":"2019","unstructured":"Birnie K, Hundert A, Lalloo C, Nguyen C, Stinson J. Recommendations for selection of self-report pain intensity measures in children and adolescents: a systematic review and quality assessment of measurement properties. Pain. 2019;160(1):5\u201318.","journal-title":"Pain"},{"key":"2113_CR17","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1016\/S0304-3959(01)00314-1","volume":"93","author":"C Hicks","year":"2001","unstructured":"Hicks C, von Baeyer C, Spafford P, van Korlaar I, Goodenough B. The Faces Pain Scale\u2013Revised: toward a common metric in pediatric pain measurement. Pain. 2001;93:2173\u201383.","journal-title":"Pain"},{"issue":"2","key":"2113_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/ajmg.a.30579","volume":"134A","author":"SJ Swiedler","year":"2005","unstructured":"Swiedler SJ, Beck M, Bajbouj M, Giugliani R, Schwartz I, Harmatz P, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): Clinical Survey of MPS VI. Am J Med Genet. 2005;134A(2):144\u201350.","journal-title":"Am J Med Genet"},{"issue":"5","key":"2113_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/AJP.0b013e318192bfb1","volume":"25","author":"JI Gold","year":"2009","unstructured":"Gold JI, Mahrer NE, Yee J, Palermo TM. Pain, fatigue, and health-related quality of life in children and adolescents with chronic pain. Clin J Pain. 2009;25(5):407\u201312.","journal-title":"Clin J Pain"},{"issue":"5","key":"2113_CR20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.jval.2018.01.015","volume":"21","author":"D Phillips","year":"2018","unstructured":"Phillips D, Leiro B. Clinical outcome assessments: use of normative data in a pediatric rare disease. Value Health. 2018;21(5):508\u201314.","journal-title":"Value Health"},{"key":"2113_CR21","unstructured":"HealthMeasures. NIH Toolbox: Motor Measures [Internet]. 2021 [cited 2021 Jun 3]. Available from: https:\/\/www.healthmeasures.net\/explore-measurement-systems\/nih-toolbox\/intro-to-nih-toolbox\/motor"},{"key":"2113_CR22","doi-asserted-by":"crossref","unstructured":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111\u20137.","DOI":"10.1164\/ajrccm.166.1.at1102"},{"issue":"6","key":"2113_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/adc.2007.123653","volume":"93","author":"AE Lammers","year":"2008","unstructured":"Lammers AE, Hislop AA, Flynn Y, Haworth SG. The 6-minute walk test: normal values for children of 4\u201311 years of age. Arch Dis Child. 2008;93(6):464\u20138.","journal-title":"Arch Dis Child"},{"issue":"4","key":"2113_CR24","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jpeds.2006.12.052","volume":"150","author":"R Geiger","year":"2007","unstructured":"Geiger R, Strasak A, Treml B, Gasser K, Kleinsasser A, Fischer V, et al. Six-minute walk test in children and adolescents. J Pediatr. 2007;150(4):395\u20139.","journal-title":"J Pediatr."},{"key":"2113_CR25","unstructured":"HealthMeasures. NIH Toolbox: Interpret Scores [Internet]. 2021 [cited 2021 Jun 3]. Available from: https:\/\/www.healthmeasures.net\/score-and-interpret\/interpret-scores\/nih-toolbox"},{"key":"2113_CR26","doi-asserted-by":"crossref","unstructured":"Harmatz P, Giugliani R, Schwartz IV D, Guffon N, Teles EL, Miranda MCS, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94(4):469\u201375.","DOI":"10.1016\/j.ymgme.2008.04.001"},{"key":"2113_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.physio.2021.03.002","volume":"112","author":"T Del Corral","year":"2021","unstructured":"Del Corral T, Vivas-Mateos J, Castillo-Pelaz M, Aguilar-Zafra S, L\u00f3pez-de-Uralde-Villanueva I. Development of stratified normative data and reference equations for the timed up and down stairs test for healthy children 6\u201314 years of age. Physiotherapy. 2021;112:31\u201340.","journal-title":"Physiotherapy"},{"issue":"2","key":"2113_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ymgme.2014.10.015","volume":"114","author":"PR Harmatz","year":"2015","unstructured":"Harmatz PR, Mengel KE, Giugliani R, Valayannopoulos V, Lin S-P, Parini R, et al. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. Mol Genet Metab. 2015;114(2):186\u201394.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"2113_CR29","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Fleming TR, Harmatz P, Hughes D, Jones SA, Lin S-P, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomised placebo-controlled study. J Inherit Metab Dis. 2014;37(6):979\u201390.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"2113_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13023-017-0634-0","volume":"12","author":"D Hughes","year":"2017","unstructured":"Hughes D, Giugliani R, Guffon N, Jones SA, Mengel KE, Parini R, et al. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa. Orphanet J Rare Dis. 2017;12(1):98.","journal-title":"Orphanet J Rare Dis"},{"key":"2113_CR31","doi-asserted-by":"crossref","unstructured":"Bruininks RH, Bruininks BD. Bruininks-Oseretsky Test of Motor Proficiency | Second Edition [Internet]. 2005 [cited 2021 Jun 3]. Available from: https:\/\/www.pearsonassessments.com\/store\/usassessments\/en\/Store\/Professional-Assessments\/Motor-Sensory\/Bruininks-Oseretsky-Test-of-Motor-Proficiency-%7C-Second-Edition\/p\/100000648.html","DOI":"10.1037\/t14991-000"},{"issue":"1","key":"2113_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymgme.2021.03.006","volume":"133","author":"P Garcia","year":"2021","unstructured":"Garcia P, Phillips D, Johnson J, Martin K, Randolph LM, Rosenfeld H, et al. Long-term outcomes of patients with mucopolysaccharidosis VI treated with galsulfase enzyme replacement therapy since infancy. Mol Genet Metab. 2021;133(1):100\u20138.","journal-title":"Mol Genet Metab"},{"key":"2113_CR33","doi-asserted-by":"publisher","unstructured":"Aslam R, van Bommel ACM, Hendriksz CJ, Jester A. Subjective and Objective Assessment of Hand Function in Mucopolysaccharidosis IVa Patients. In: Zschocke J, Gibson KM, Brown G, Morava E, Peters V, editors. JIMD Reports \u2013 Case and Research Reports, 2012\/6 [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012 [cited 2020 Mar 18]. p. 59\u201365. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/8904_2012_179","DOI":"10.1007\/8904_2012_179"},{"issue":"2","key":"2113_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1590\/S0021-75572008000200007","volume":"84","author":"A Cardoso-Santos","year":"2008","unstructured":"Cardoso-Santos A, Azevedo ACMM, Fagondes S, Burin MG, Giugliani R, Schwartz IVD. Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome): assessment of joint mobility and grip and pinch strength. J Pediatr (Rio J). 2008;84(2):130\u20135.","journal-title":"J Pediatr (Rio J)"},{"key":"2113_CR35","unstructured":"Centers for Disease Control and Prevention. Normal Joint Range of Motion Study | CDC [Internet]. Centers for Disease Control and Prevention. 2018 [cited 2021 Jun 3]. Available from: https:\/\/www.cdc.gov\/ncbddd\/jointrom\/index.html"},{"key":"2113_CR36","unstructured":"Muir SW, Corea CL, Beaupre L, MScPT Bs. Evaluating change in clinical status: reliability and measures of agreement for the assessment of glenohumeral range of motion. N Am J Sports Phys Ther 2010;5(3):98\u2013110."},{"key":"2113_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ymgmr.2017.08.007","volume":"13","author":"M Furujo","year":"2017","unstructured":"Furujo M, Kosuga M, Okuyama T. Enzyme replacement therapy attenuates disease progression in two Japanese siblings with mucopolysaccharidosis type VI: 10-Year follow up. Mol Genet Metab Reps. 2017;13:69\u201375.","journal-title":"Mol Genet Metab Reps"},{"issue":"1","key":"2113_CR38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/jmd2.12043","volume":"49","author":"C Haller","year":"2019","unstructured":"Haller C, Song W, Cimms T, Chen C. Individual heat map assessments demonstrate vestronidase alfa treatment response in a highly heterogeneous mucopolysaccharidosis VII study population. JIMD Rep. 2019;49(1):53\u201362.","journal-title":"JIMD Rep"},{"issue":"5","key":"2113_CR39","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00004694-199809000-00001","volume":"18","author":"L Daltroy","year":"1998","unstructured":"Daltroy L, Liang M, Fossel A, Goldberg M. The POSNA pediatric musculoskeletal functional health questionnaire: report on reliability, validity, and sensitivity to change. J Pediatric Orthopaedics. 1998;18(5):561\u201371.","journal-title":"J Pediatric Orthopaedics"},{"issue":"Suppl 11","key":"2113_CR40","doi-asserted-by":"publisher","first-page":"S371","DOI":"10.1002\/acr.20635","volume":"63","author":"SE Klepper","year":"2011","unstructured":"Klepper SE. Measures of pediatric function: Child Health Assessment Questionnaire (C-HAQ), Juvenile Arthritis Functional Assessment Scale (JAFAS), Pediatric Outcomes Data Collection Instrument (PODCI), and Activities Scale for Kids (ASK). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S371-382.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"2113_CR41","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1097\/BPO.0000000000000168","volume":"34","author":"A O\u2019Brien","year":"2014","unstructured":"O\u2019Brien A, Bompadre V, Hale S. Musculoskeletal function in patients with mucopolysaccharidosis using the pediatric outcomes data collection instrument. J Pediatric Orthopaedics. 2014;34(6):650\u20134.","journal-title":"J Pediatric Orthopaedics"},{"issue":"12","key":"2113_CR42","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37(12):1761\u20139.","journal-title":"Arthritis Rheum"},{"key":"2113_CR43","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1750-1172-8-101","volume":"8","author":"M Raluy-Callado","year":"2013","unstructured":"Raluy-Callado M, Chen W-H, Whiteman DAH, Fang J, Wiklund I. The impact of Hunter syndrome (mucopolysaccharidosis type II) on health-related quality of life. Orphanet J Rare Dis. 2013;8:101.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2113_CR44","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","volume":"37","author":"JW Varni","year":"1999","unstructured":"Varni JW, Seid M, Rode CA. The PedsQLTM: Measurement Model for the Pediatric Quality of Life Inventory. Med Care. 1999;37(2):126\u201339.","journal-title":"Med Care"},{"key":"2113_CR45","unstructured":"Varni JW. PedsQLTM (Pediatric Quality of Life InventoryTM) [Internet]. 2021 [cited 2021 Jun 3]. Available from: https:\/\/www.pedsql.org\/"},{"issue":"4","key":"2113_CR46","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10897-014-9791-7","volume":"24","author":"M Needham","year":"2015","unstructured":"Needham M, Packman W, Quinn N, Rappoport M, Aoki C, Bostrom A, et al. Health-related quality of life in patients with MPS II. J Genet Couns. 2015;24(4):635\u201344.","journal-title":"J Genet Couns"},{"key":"2113_CR47","unstructured":"International Association for the Study of Pain. Faces Pain Scale - Revised [Internet]. 2018 [cited 2021 Jun 3]. Available from: https:\/\/www.iasp-pain.org\/Education\/Content.aspx?ItemNumber=1519"},{"issue":"3","key":"2113_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1155\/2006\/197616","volume":"11","author":"CL von Baeyer","year":"2006","unstructured":"von Baeyer CL. Children\u2019s self-reports of pain intensity: scale selection, limitations and interpretation. Pain Res Manag. 2006;11(3):157\u201362.","journal-title":"Pain Res Manag"},{"key":"2113_CR49","doi-asserted-by":"crossref","unstructured":"Congedi S, Di Pede C, Scarpa M, Rampazzo A, Benini F. the complexity of pain management in children affected by Mucopolysaccharidoses. Case Rep Pediatrics. 2017;2017:e7257230.","DOI":"10.1155\/2017\/7257230"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02113-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02113-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T07:10:42Z","timestamp":1638429042000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02113-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2113"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02113-8","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"27 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was not required for this project as per Part 46.104, Protection of Human Subjects of the Electronic Code of Federal Regulations. Participants with mucopolysaccharidosis VI provided consent\/assent to participate in the focus group.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of participant quotes was obtained from the patients and\/or caregivers. Sex-specific pronouns in participant quotes have been replaced with sex-neutral pronouns, where applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"500"}}